DOI:
10.1055/s-00000020
Geburtshilfe und Frauenheilkunde
LinksClose Window
References
Telli ML, Hellyer J, Audeh W. et al.
Homologous recombination deficiency (HRD) status predicts response to standard neoadjuvant chemotherapy in patients with triple-negative or BRCA1/2 mutation-associated breast cancer.
Breast Cancer Res Treat 2018;
168: 625-630
Access:
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.